O'Connor Owen A, Amengual Jennifer, Colbourn Donald, Deng Changchun, Sawas Ahmed
a Department of Medicine, College of Physicians and Surgeons , Center for Lymphoid Malignancies, Columbia University Medical Center , New York , NY , USA.
Leuk Lymphoma. 2017 Nov;58(11):2548-2557. doi: 10.1080/10428194.2017.1306642.
It has been nearly 8 years since pralatrexate became the first drug approved by the U.S. Food and Drug Administration for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Like most drugs approved for a particular clinical indication, as much or more is learned once it enters mainstream use as in the years leading up to regulatory approval. Over the past several years, many diverse lines of research have shed new insight into both the agent, and the diseases it treats. In this review, we will bring the reader up to date on the many new aspects related to pralatrexate's pharmacology, activity across the panoply of T-cell lymphoproliferative malignancies, as well as some new and emerging guidelines that are likely to improve its safety profile. Finally, the review will close with the many new lines of evidence building a rationale for the combination of these novels: novel combination, and the vision for new platforms in PTCL care.
普拉曲沙成为美国食品药品监督管理局批准用于治疗复发或难治性外周T细胞淋巴瘤（PTCL）的首款药物已近8年。与大多数获批用于特定临床适应症的药物一样，其进入主流使用后所了解到的信息与监管批准前几年所了解到的一样多，甚至更多。在过去几年中，许多不同的研究方向为这种药物及其所治疗的疾病带来了新的见解。在本综述中，我们将向读者介绍与普拉曲沙药理学、在各种T细胞淋巴增殖性恶性肿瘤中的活性以及一些可能改善其安全性的新出现的指南相关的诸多新情况。最后，本综述将以众多新的证据线索作结，这些线索为这些新疗法的联合应用——新联合疗法以及PTCL治疗新平台的愿景——提供了理论依据。
